Sequential angiogenic blockade for the treatment of recurrent ovarian cancer.

Abstract

5083 Background: Ovarian cancer (ov ca) growth is driven by angiogenesis; drugs that block angiogenesis can result in anti-ov ca activity. This study sought to sequentially block angiogenesis by adding stepwise antiangiogenic agents targeting different aspects of the angiogenic cascade. Methods: Objectives were to assess the safety of sequential bevacizumab (bev) and oral low dose cyclophosphamide (Cy) and assess proportion of patients who remain on study at 3 months; others were toxicity, RR, and PFS. Eligibility: recurrent ov, tubal, or peritoneal ca, max of 2 lines of therapy for recurrent ca (biologic therapies included), platinum resistant or sensitive recurrence, ECOG PS of 0 or 1, measurable cancer by RECIST or CA125, no preexisting significant hypertension, and no evidence of SBO or impending SBO. Pts started on bev 15 mg/kg IV q21 days and were assessed radiographically every 2 cycles. If CR, PR, or SD and no significant toxicities occurred, patients continued on bev. If pts had PD and were clini...